Randomized trial evaluates a quadruple agonist's effects on weight and glucose levels in obesity models, implying therapeutic promise.
Key Points
The study aims to assess the pharmacological efficacy of a novel GLP-1/GIP/glucagon/gastrin quadruple agonist in improving glycemic control and reducing obesity.
In vitro receptor activation measured in CHO-K1 cells using cAMP or p-ERK assays.
SGLT2 protein expression analyzed in HK-2 cells via Immunoblot.
C57BL/6J mice administered the quadruple agonist for 21 days to evaluate body weight, food intake, and fasting glucose levels.
Quadruple agonist #1 and #2 led to significant body weight reductions of 59.4% and 54.7% compared to vehicle (-0.7%; p<0.001).
Cumulative food intake suppression was 75.8% and 61.4% for the quadruple agonists vs. vehicle group.
Fasting glucose levels in treated mice decreased to 101.8 mg/dL and 69.5 mg/dL compared to 222.9 mg/dL for vehicle.